Cases & Investigations
CVRx, Inc.
Type: Investigations
Stock Symbol: NASDAQ: CVRX
Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx") common stock (NASDAQ: CVRX).
CVRx is a medical device company specializing in Barostim, a pacemaker-like therapeutic device.
Beginning in April 2024, CVRx disclosed operational challenges within its sales organization following leadership transitions. Company executives, including Chief Executive Officer Kevin Hykes, publicly assured investors that these disruptions had been resolved and that the sales force had stabilized. This message was reiterated through multiple earnings calls, most recently in October 2024.
However, in April 2025, CVRx revealed that salesforce issues persisted, with a significant portion of its sales team consisting of newly hired representatives still ramping up productivity. By May 2025, the company acknowledged that the scope of necessary salesforce restructuring had been substantially underestimated, requiring the hiring of 25% of current territory managers within a three-month period.
Following these announcements, CVRx's stock price declined sharply: 46.3% on April 8, 2025, and an additional 38.7% on May 9, 2025, both on heavy trading volume.
Investors who lost over $10,000 trading in CVRx common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com.
Contact Instructions